Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by StockNews.com to “Buy”

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday.

TEVA has been the subject of a number of other research reports. Piper Sandler reiterated an “overweight” rating and set a $20.00 price target (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Monday, February 5th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a report on Friday, March 8th. Barclays lifted their price target on Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, May 9th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $14.22.

View Our Latest Research Report on TEVA

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.59 on Monday. The stock has a market capitalization of $18.60 billion, a price-to-earnings ratio of -40.46, a PEG ratio of 1.94 and a beta of 1.04. The business has a 50-day moving average of $14.19 and a 200-day moving average of $12.20. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $17.13.

Insider Activity

In other news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 141,900 shares of company stock worth $2,013,861. Corporate insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Bank of New York Mellon Corp grew its stake in shares of Teva Pharmaceutical Industries by 1.1% during the third quarter. Bank of New York Mellon Corp now owns 1,902,235 shares of the company’s stock worth $19,403,000 after buying an additional 19,906 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $164,000. Private Advisor Group LLC grew its stake in shares of Teva Pharmaceutical Industries by 13.8% during the third quarter. Private Advisor Group LLC now owns 14,770 shares of the company’s stock worth $147,000 after buying an additional 1,790 shares during the last quarter. Nomura Asset Management Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 2.1% during the third quarter. Nomura Asset Management Co. Ltd. now owns 363,526 shares of the company’s stock worth $3,708,000 after buying an additional 7,618 shares during the last quarter. Finally, Signaturefd LLC grew its stake in shares of Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after buying an additional 2,394 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Further Reading

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.